Achieving Optimal Treatment Targets and Minimal Disease Activity with Upadacitinib for Moderate-to-Severe Atopic Dermatitis: Integrated Analysis of Phase 3 Studies (Measure Up 1 and 2)Jonathan I. Silverberg, Andreas Wollenberg, Andrew Pink et al.|Dermatology and Therapy|2025Cited by 4
729 - A phase 2b, randomized, double-blinded, parallel-group, placebo-controlled, international, multicenter, study to evaluate the efficacy and safety of rezpegaldesleukin in adults with moderate-to-severe atopic dermatitisMelinda Gooderham, David Rosmarin, Charles Lynde et al.|British Journal of Dermatology|2024Cited by 2